In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier.
Multidrug resistance is one of major obstacles to the effective cancer chemotherapy. To address this issue, we developed the effective circumvention of multidrug resistance in cancer cells by a yolk-shell Fe3O4@MgSiO3 nanoplatform with the polymerpoly(ethylene glycol) and folic acid modifications can achieve active targeted delivery of anti-cancer drug by using combined magnetic and ligand targeting. The direct intracellular drug delivery of doxorubicin by nanocarrier was much more effectively than free DOX for multidrug resistant Hep-G2/MDR cancer cells. Besides the excellent biocompatibility, high drug loading efficiency, dual-targeting delivery, and controlled releasing behavior, in vivo experiments demonstrate that this nanocarrier can specifically deliver and concentrate doxorubicin hydrochloride in tumor sites to overcome drug resistance. It follows an alternative strategy for effective chemotherapy against drug resistant cancers by using rationally designed nanomaterial.
Centre for Biomaterials and Biopathways, Department of Chemistry, Zhejiang University, Hangzhou, Zhejiang, 310027, PR China.
Yang
Y
Wang
Centre for Biomaterials and Biopathways, Department of Chemistry, Zhejiang University, Hangzhou, Zhejiang, 310027, PR China.
Ruibo
R
Zhao
Clinical Research Centre, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, PR China.
Shibing
S
Wang
Centre for Biomaterials and Biopathways, Department of Chemistry, Zhejiang University, Hangzhou, Zhejiang, 310027, PR China.
Zhaoming
Z
Liu
Centre for Biomaterials and Biopathways, Department of Chemistry, Zhejiang University, Hangzhou, Zhejiang, 310027, PR China; Qiushi Academy for Advanced Studies, Zhejiang University, Hanghzou, Zhejiang 310027, China. Electronic address: rtang@zju.edu.cn.
Ruikang
R
Tang
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use*; D004337:Drug Carriers / Q000737:chemistry*; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004530:Egg Yolk / Q000737:chemistry; D005290:Ferric Compounds / Q000737:chemistry; D005434:Flow Cytometry; D005492:Folic Acid / Q000494:pharmacology; D056945:Hep G2 Cells; D006801:Humans; D042541:Intracellular Space / Q000378:metabolism; D017633:Magnesium Silicates / Q000737:chemistry; D060328:Magnetic Phenomena; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D011092:Polyethylene Glycols / Q000737:chemistry; D016062:Porosity; D013696:Temperature; D014961:X-Ray Diffraction
D000970:Antineoplastic Agents; D004337:Drug Carriers; D005290:Ferric Compounds; D017633:Magnesium Silicates; C000499:ferric oxide; D011092:Polyethylene Glycols; D004317:Doxorubicin; D005492:Folic Acid
Combined target effect; Drug resistant cancer; In vivo distribution; Nanoparticle; Yolk-shell structure